Opus Genetics (IRD) Competitors $1.13 -0.02 (-1.74%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$1.06 -0.07 (-6.19%) As of 03/25/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock IRD vs. CGEN, ZNTL, ACTU, OGI, DERM, ALEC, SAVA, LXEO, TELO, and PRQRShould you be buying Opus Genetics stock or one of its competitors? The main competitors of Opus Genetics include Compugen (CGEN), Zentalis Pharmaceuticals (ZNTL), Actuate Therapeutics (ACTU), Organigram (OGI), Journey Medical (DERM), Alector (ALEC), Cassava Sciences (SAVA), Lexeo Therapeutics (LXEO), Telomir Pharmaceuticals (TELO), and ProQR Therapeutics (PRQR). These companies are all part of the "pharmaceutical products" industry. Opus Genetics vs. Compugen Zentalis Pharmaceuticals Actuate Therapeutics Organigram Journey Medical Alector Cassava Sciences Lexeo Therapeutics Telomir Pharmaceuticals ProQR Therapeutics Compugen (NASDAQ:CGEN) and Opus Genetics (NASDAQ:IRD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, community ranking and media sentiment. Does the MarketBeat Community prefer CGEN or IRD? Compugen received 306 more outperform votes than Opus Genetics when rated by MarketBeat users. However, 100.00% of users gave Opus Genetics an outperform vote while only 64.24% of users gave Compugen an outperform vote. CompanyUnderperformOutperformCompugenOutperform Votes30964.24% Underperform Votes17235.76% Opus GeneticsOutperform Votes3100.00% Underperform VotesNo Votes Does the media favor CGEN or IRD? In the previous week, Opus Genetics had 7 more articles in the media than Compugen. MarketBeat recorded 9 mentions for Opus Genetics and 2 mentions for Compugen. Compugen's average media sentiment score of 1.66 beat Opus Genetics' score of 0.69 indicating that Compugen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compugen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Opus Genetics 1 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate CGEN or IRD? Compugen currently has a consensus target price of $4.00, indicating a potential upside of 154.78%. Opus Genetics has a consensus target price of $8.00, indicating a potential upside of 607.96%. Given Opus Genetics' higher probable upside, analysts clearly believe Opus Genetics is more favorable than Compugen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Compugen 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Opus Genetics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation & earnings, CGEN or IRD? Opus Genetics has lower revenue, but higher earnings than Compugen. Compugen is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCompugen$27.86M5.03-$18.75M-$0.16-9.81Opus Genetics$8.38M4.26-$9.99M-$1.09-1.04 Which has more risk & volatility, CGEN or IRD? Compugen has a beta of 2.98, meaning that its stock price is 198% more volatile than the S&P 500. Comparatively, Opus Genetics has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500. Do institutionals and insiders hold more shares of CGEN or IRD? 12.2% of Compugen shares are owned by institutional investors. Comparatively, 15.0% of Opus Genetics shares are owned by institutional investors. 9.5% of Compugen shares are owned by company insiders. Comparatively, 6.6% of Opus Genetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is CGEN or IRD more profitable? Compugen has a net margin of 2.67% compared to Opus Genetics' net margin of -324.45%. Compugen's return on equity of 2.62% beat Opus Genetics' return on equity.Company Net Margins Return on Equity Return on Assets Compugen2.67% 2.62% 1.36% Opus Genetics -324.45%-63.65%-56.94% SummaryCompugen beats Opus Genetics on 12 of the 17 factors compared between the two stocks. Remove Ads Get Opus Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for IRD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IRD vs. The Competition Export to ExcelMetricOpus GeneticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$35.67M$6.99B$5.68B$8.30BDividend YieldN/A2.73%4.55%4.02%P/E Ratio-1.047.2324.5819.25Price / Sales4.26232.30388.1194.32Price / CashN/A65.6738.1634.64Price / Book0.516.617.074.46Net Income-$9.99M$142.13M$3.19B$247.07M7 Day Performance-1.74%-1.51%-0.92%0.14%1 Month Performance5.61%-3.46%3.58%-4.39%1 Year PerformanceN/A-5.32%14.15%4.85% Opus Genetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IRDOpus Genetics2.8744 of 5 stars$1.13-1.7%$8.00+608.0%N/A$35.67M$8.38M-1.0414Upcoming EarningsHigh Trading VolumeCGENCompugen2.1315 of 5 stars$1.62+3.2%$4.00+146.9%-37.9%$144.56M$27.86M81.0070Positive NewsZNTLZentalis Pharmaceuticals2.0616 of 5 stars$1.98+3.7%$8.24+316.4%-86.2%$141.11M$40.56M-0.80160Gap UpACTUActuate TherapeuticsN/A$7.20+6.7%$20.00+177.8%N/A$140.63MN/A0.0010OGIOrganigram0.6999 of 5 stars$1.11flatN/A-57.5%$140.10M$166.12M-2.92860Positive NewsDERMJourney Medical2.5877 of 5 stars$6.54+13.9%$9.67+47.8%+121.9%$136.62M$57.77M-6.9690High Trading VolumeALECAlector3.7363 of 5 stars$1.37+1.5%$3.50+155.5%-78.4%$135.75M$100.56M-0.81270SAVACassava Sciences3.9112 of 5 stars$2.80-1.4%$111.50+3,882.1%-90.4%$135.26MN/A-2.0330Analyst ForecastNews CoverageGap DownLXEOLexeo Therapeutics2.515 of 5 stars$4.09+50.9%$23.60+477.0%-69.6%$135.24M$650,000.00-1.2958Earnings ReportAnalyst ForecastNews CoverageGap UpHigh Trading VolumeTELOTelomir Pharmaceuticals1.8723 of 5 stars$4.53-0.7%$15.00+231.1%-21.8%$134.83MN/A-7.811Gap DownPRQRProQR Therapeutics2.6206 of 5 stars$1.65flat$9.50+475.8%-32.6%$134.77M$18.91M-5.16180Gap Up Remove Ads Related Companies and Tools Related Companies Compugen Alternatives Zentalis Pharmaceuticals Alternatives Actuate Therapeutics Alternatives Organigram Alternatives Journey Medical Alternatives Alector Alternatives Cassava Sciences Alternatives Lexeo Therapeutics Alternatives Telomir Pharmaceuticals Alternatives ProQR Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IRD) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredHere’s Why Tesla Insiders are Dumping SharesTesla has been on a losing streak ever since Elon Musk first visited the White House in early 2025. Our res...Behind the Markets | SponsoredThis Crypto Is Set to Explode in FebruaryBryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opus Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Opus Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IRD Stock Free IRD Stock Alerts